BiotechTube

BMN165 20mg/day + BMN165 40mg/day + Placebo

Phase 3Completed
1 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Phenylketonuria (PKU)

Conditions

Phenylketonuria (PKU)

Trial Timeline

Jul 29, 2013 → Feb 5, 2019

NCT ID
NCT01889862

About BMN165 20mg/day + BMN165 40mg/day + Placebo

BMN165 20mg/day + BMN165 40mg/day + Placebo is a phase 3 stage product being developed by BioMarin Pharmaceutical for Phenylketonuria (PKU). The current trial status is completed. This product is registered under clinical trial identifier NCT01889862. Target conditions include Phenylketonuria (PKU).

What happened to similar drugs?

7 of 20 similar drugs in Phenylketonuria (PKU) were approved

Approved (7) Terminated (1) Active (12)
❌SYNB1934v1 + PlaceboSynlogicPhase 3
🔄Kuvan®MerckPhase 3
✅Kuvan®MerckApproved
🔄Sapropterin dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3
🔄sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
✅saproterin dihydrochlorideBioMarin PharmaceuticalApproved
✅Pegvaliase + MethotrexateBioMarin PharmaceuticalApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01889862Phase 3Completed

Competing Products

20 competing products in Phenylketonuria (PKU)

See all competitors
ProductCompanyStageHype Score
mRNA-3210ModernaPhase 2
0
SYNB1934v1 + PlaceboSynlogicPhase 3
22
SYNB1618 + PlaceboSynlogicPhase 1/2
22
SYNB1618 + SYNB1934SynlogicPhase 2
25
Kuvan®MerckPhase 3
40
Kuvan®MerckApproved
43
SAR444836SanofiPhase 1/2
36
KuvanBioMarin PharmaceuticalPre-clinical
15
rAvPAL-PEGBioMarin PharmaceuticalPhase 2
32
rAvPAL-PEGBioMarin PharmaceuticalPhase 2
32
Sapropterin (Kuvan)BioMarin PharmaceuticalPre-clinical
23
BMN 165 (rAvPAL-PEG)BioMarin PharmaceuticalPhase 2
32
BMN 307BioMarin PharmaceuticalPhase 1/2
33
SapropterinBioMarin PharmaceuticalPre-clinical
23
Sapropterin dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3
37
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
37
saproterin dihydrochlorideBioMarin PharmaceuticalApproved
40
sapropterin dihydrochloride + Moxifloxacin + Moxifloxacin placeboBioMarin PharmaceuticalPhase 1
26
PegvaliaseBioMarin PharmaceuticalPre-clinical
30
PegvaliaseBioMarin PharmaceuticalPre-clinical
23